Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

NCT05642572 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT05642572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05642572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2023
Completion date
June 30, 2028
Enrollment
66 (estimated)
Sites
454

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8